Presentations on Genomics

FDA Genomics Group Presentations in 2010-2011
 

2011

Zineh I, Genomics in Drug Development and Regulatory Decision-Making, 14th Meeting of the Roundtable on Translating Genomic-Based Research for Health, Institute of Medicine, July 19-20, 2011, Washington, DC

Zineh I, A Risk/Benefit View of Safety Pharmacogenomics, American Society for Experimental Pharmacology and Therapeutics (ASPET) Annual Meeting, April 13-14, 2011, Washington, DC

Pacanowski MA, Tailored Antiplatelet Therapy: Is it Time for Personalized Medicine? An FDA Perspective, American College of Cardiology Annual Scientific Sessions, April 2-5, 2011, New Orleans, LA

Amur S, Understanding Personalized Medicine, Related Regulations and Their Impact on Healthcare Policies, 3rd Annual Forum for Payers on Personalized Medicine, March 24, 2011, Washington, DC

Pacanowski MA, Applying Pharmacokinetics and Pharmacodynamics for Regulatory Submissions: Pharmacogenomics, Pharmaceutical Education and Research Institute, March 28-29, 2011, Arlington, VA

Zineh I, Pharmacogenetics: Global Regulatory Issues, 13th American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting, February 24-26, 2011, Bethesda, MD

2010

Zineh I, What's the FDA Doing with Pharmacogenetic Data? American Heart Association Scientific Sessions, November 14-17, 2010, Chicago, IL

Zineh I, Pharmacogenomics: Scientific and Regulatory Considerations, 13th Annual Land O’ Lakes Conference on Drug Metabolism/Applied Pharmacokinetcs, September 12-16, 2010, Merrimac, WI

Amur S, Relabeling Drugs with Genomic Information for Improved Risk/Benefit, 46th DIA Annual Meeting, June 16, 2010, Washington, DC

Amur S, How Will Genetic Predictors Be Translated into Clinical Management? The End Goal: FDA Perspective. “Pharmacogenomics: A Path towards Personalized HIV Care Workshop,” June16-17, 2010, Rockville, MD

Pacanowski MA, The Path from Scoping to Integrated Review for Genomic Data, 46th DIA Annual Meeting, June 16, 2010, Washington, DC